Case Report. Diagnostic Challenges: Liver Metastases from Mammary Gland Origin or Cholangiocarcinoma?

biopsy breast immunohistochemistry markers tumor

Journal

International journal of women's health
ISSN: 1179-1411
Titre abrégé: Int J Womens Health
Pays: New Zealand
ID NLM: 101531698

Informations de publication

Date de publication:
2023
Historique:
received: 28 02 2023
accepted: 11 07 2023
medline: 3 8 2023
pubmed: 3 8 2023
entrez: 3 8 2023
Statut: epublish

Résumé

Liver metastases are secondary malignant tumor formations due to the dissemination of primary malignant tumors, which are often the first clinical manifestation of mammary cancer. We present the case of a 52-year-old female patient from an urban area who came to the walk-in service at the "Sf. Ap. Andrei" Emergency County Hospital, Galati, for laboratory investigations. These revealed a significant increase in CA 15-3 tumor markers and a slight increase in CA 125 and CA 19-9 markers; however, clinical examination did not reveal tumors in the breast and there were no axillary adenopathies. CT exam revealed a large tumor formation in the hepatic right lobe and, close to it, a smaller one. The mammograph showed millimetric lesions at the level of the left mammary gland and bilateral axillary adenopathies. Subsequently, the patient underwent two liver biopsies in two different hospitals, which produced different histological and immunohistochemical results. PET-CT drew attention to a lung tumor and disclosed a different origin of metastases. In the end, correlating all investigations, the final diagnosis was cholangiocarcinoma with liver metastases and lung tumor with lung and bone metastases.

Identifiants

pubmed: 37534051
doi: 10.2147/IJWH.S408055
pii: 408055
pmc: PMC10391531
doi:

Types de publication

Case Reports

Langues

eng

Pagination

1205-1211

Informations de copyright

© 2023 Tocu et al.

Déclaration de conflit d'intérêts

The authors report no conflicts of interest in this work.

Références

Ther Clin Risk Manag. 2018 Jan 22;14:149-155
pubmed: 29403282
Indian J Med Paediatr Oncol. 2009 Jan;30(1):1-8
pubmed: 20668599
Am J Surg Pathol. 2004 Nov;28(11):1506-12
pubmed: 15489655
Cancers (Basel). 2018 Apr 05;10(4):
pubmed: 29621151
Acta Med Acad. 2015;44(1):39-46
pubmed: 26062696
Balkan J Med Genet. 2012 Dec;15(2):35-46
pubmed: 24052730
Rom J Morphol Embryol. 2013;54(2):447-50
pubmed: 23771097
Headache. 2013 Nov-Dec;53(10):1541-7
pubmed: 24266334
Mol Clin Oncol. 2021 Sep;15(3):178
pubmed: 34276997
Dis Markers. 2019 Jul 17;2019:2568069
pubmed: 31396293
Rom J Morphol Embryol. 2018;59(3):945-948
pubmed: 30534838
Folia Morphol (Warsz). 2019;78(4):888-892
pubmed: 30949998
Breast J. 2019 May;25(3):418-424
pubmed: 30925636

Auteurs

George Tocu (G)

Pharmaceutical Sciences Department, "Dunărea de Jos" University, Galati, Romania.

Ioana Teodora Popa (IT)

Clinical Surgical Department, Fundeni Clinical Institute, Bucharest, Romania.

Iuliana Ivan (I)

Oncology Department of "Sf. Apostol Andrei" Emergency County Hospital, Galati, Romania.

Lucretia Anghel (L)

Clinical Medical Department, "Dunărea de Jos" University, Galati, Romania.

Luiza A Nechita (LA)

Clinical Medical Department, "Dunărea de Jos" University, Galati, Romania.

Carmina Liana Musat (CL)

Morphological and Functional Sciences Department, "Dunarea de Jos" University, Galati, Romania.

Laura Florentina Rebegea (LF)

Clinical Medical Department, "Dunărea de Jos" University, Galati, Romania.

Dana Tutunaru (D)

Pharmaceutical Sciences Department, "Dunărea de Jos" University, Galati, Romania.

Classifications MeSH